Addition of Isatuximab to RVd As Induction Therapy for Newly-Diagnosed, Transplant-Eligible MM Pts
Phase III trial of RVd induction with or without isatuximab in newly diagnosed myelomaПодробнее
IMROZ- IsaRVd vs RVd in Newly Diagnosed Transplant Ineligible MM | Thierry Facon, MD | EHA 2024Подробнее
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for NDMM patientsПодробнее
Isatuximab with VRd in Pts with Newly Diagnosed Multiple Myeloma Non-Eligible for TransplantПодробнее
Isatuximab, Carfilzomib, Lenalidomide, and Dex (Isa-KRd) in Pts with High-Risk Newly Diagnosed MMПодробнее
DARA+RVd in Pts w/Transplant Eligible Newly Diagnosed Multiple Myeloma after 24 Months MaintenanceПодробнее
MajesTEC-5: Phase II study of Tec-based induction in transplant-eligible newly diagnosed myelomaПодробнее
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in ...Подробнее
Debate: Optimal Induction Therapy for Newly Diagnosed Transplant Eligible Myeloma - TripletsПодробнее
The safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in NDMMПодробнее
Overall Survival Results in Transplant-Ineligible Newly Diagnosed MM pts: Phase 3 MAIA StudyПодробнее
GRIFFIN updates: D-RVd vs RVd in transplant-eligible patients with newly diagnosed multiple myelomaПодробнее
Isatuximab, Lenalidomide, Bortezomib, and Dex for Newly-Diagnosed Multiple Myeloma: GMMG-HD7Подробнее
Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myelomaПодробнее
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myelomaПодробнее
KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaПодробнее
Stem cell mobilization with Dara-RVD induction in newly diagnosed myeloma: a real-world experienceПодробнее
Dr. Tiffany Richards Explains a New Indication for Sarclisa in Newly Diagnosed Myeloma PatientsПодробнее
Treatment for Transplant Eligible Myeloma Patients: Doublets-Triplets?Подробнее
